FDA Clears Tests That Allow for On-Site Therapeutic Monitoring of Adalimumab, Infliximab

The FDA has granted marketing authorization to Procise ADL and Procise IFX intended to measure adalimumab and infliximab levels, respectively.

Related Keywords

Larry Mimms ,Drug Administration ,